Skip to main
  1. Stocks
  2. Transmedics Group Inc
  3. Forecast
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 36%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group is viewed favorably because its core Organ Care System is gaining traction across liver, heart, and lung transplant markets, with 3Q26 revenue of $203M and non-GAAP EPS of $0.51 beating consensus while organic revenue growth accelerated to 35% from 21% in 2Q26. The company’s outlook is further strengthened by raised 2026 revenue guidance to $764M-$774M, expanding liver sales of $150M, and multiple regulatory and clinical catalysts, including completion of ENHANCE Part A and FDA IDE approval for ENHANCE Part B and DENOVO. Despite near-term margin pressure from growth investments, the platform’s large underpenetrated market, improving operating leverage, and potential incremental demand from CHOPS, OCS Kidney, and international expansion support a constructive long-term fundamental view.

Bears say

TransMedics Group is facing a fundamentally fragile outlook because its revenue base is concentrated in a narrow OCS platform, with limited product diversification and reliance on fewer than 100 transplant centers in the US. Adoption risk remains high as the company must displace cold storage with a novel model that still lacks a specific US reimbursement code, while reimbursement cuts, regulatory delays, or government scrutiny could materially pressure demand and estimates. Financially, the outlook is further weakened by rising fixed costs, with quarterly interest expense lifted to $7.2M from $3.6M and FY26 total interest expense raised to $28.8M, adding strain to execution.

TMDX has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 36% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

TMDX Analyst Forecast & Price Prediction

Get the latest TMDX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TMDX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 11 analysts, TMDX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $111.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $111.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


TMDX Analyst Forecast & Price Prediction

Get the latest TMDX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TMDX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TMDX stock data and trends